Brief: Jasper Therapeutics Says Dosing To Commence In Q4 2024, Initial Data In H2 2025
10/09/2024 13:24
Sept 10 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES HEALTH CANADA CLEARANCE OF
CLINICAL TRIAL APPLICATION FOR PHASE 1B/2A STUDY OF BRIQUILIMAB
IN ASTHMA
* JASPER THERAPEUTICS INC - DOSING TO COMMENCE IN Q4 2024,
INITIAL
DATA IN H2 2025
Source text for Eikon: ID:nGNX3jGhg4
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma